α7 Nicotinic receptor agonist-1 can be used in the research of psychiatric disorders (such as schizophrenia, mania or bipolar disorder, and anxiety disorders) and cognitive impairments (such as Alzheimer's disease, learning deficits, cognitive deficits, attention deficits, memory loss, dementia with Lewy bodies, and attention deficit hyperactivity disorder).